Ending the year in debate

Article

The holiday season is upon us again and we are about to close the door on another year, but before we do, I would firstly like to say a big thank you to all of you for your continued support of our publication throughout this year.

The holiday season is upon us again and we are about to close the door on another year, but before we do, I would firstly like to say a big thank you to all of you for your continued support of our publication throughout this year. The OTE team and I have really enjoyed working with you and meeting with you while we've been out and about, and we look forward to doing so in 2009.

But before we say goodbye to 2008, we have a real treat in store for you. We are ending the year with a series of debates on some of the most controversial topics in ophthalmology. The 2008 debates series raises important issues that made it to the podium this year. So have a look at our debates to read what some of the world's eminent surgeons had to say when they came head-to-head on some of the most important issues in your industry.

On a separate note, I would like to take this opportunity to announce that we are about to have a facelift! Yes, the first issue of OTE in 2009 will have a new look. We're going for a new size issue that will be packed with more content than before. We've also changed our weekly e-newsletter, which will be going out on Wednesdays rather than Mondays. If you've not subscribed already, just go to www.oteurope.com/enews to take advantage of this free, weekly breaking news service. We hope you like the changes. As always, I would be really happy to hear your thoughts so please do drop me an email to let me know what you think.

Thank you once again for another great year. Let's enter 2009 with optimism and hope for continued successes. I know I will!

Happy holidays everyone.

Best wishes,

Fedra Pavlou
Editor
fpavlou@advanstar.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.